...
cort-img

Corcept Therapeutics Incorporated, Common Stock

CORT

NAQ

$52.17

+$1.27

(2.5%)

1D
Industry: Pharmaceuticals Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$5.33B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
40.3968
Volume info-icon
This is the total number of shares traded during the most recent trading day.
260.02K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.46
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$20.84 L
$62.22 H
$52.17

About Corcept Therapeutics Incorporated, Common Stock

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California. more

Industry: PharmaceuticalsSector: Health Care

Returns

Time FrameCORTSectorS&P500
1-Week Return-5.39%-0.33%-1.49%
1-Month Return-11.62%-4.57%-0.37%
3-Month Return18.57%-9.96%3.89%
6-Month Return70.55%-5.67%9.34%
1-Year Return60.92%2.53%25.19%
3-Year Return165.9%-1.43%24.7%
5-Year Return313.06%34.73%85.39%
10-Year Return1674.49%102.14%187.19%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue306.49M353.87M365.98M401.86M482.38M[{"date":"2019-12-31","value":63.54,"profit":true},{"date":"2020-12-31","value":73.36,"profit":true},{"date":"2021-12-31","value":75.87,"profit":true},{"date":"2022-12-31","value":83.31,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue5.50M5.58M5.28M5.38M6.48M[{"date":"2019-12-31","value":84.93,"profit":true},{"date":"2020-12-31","value":86.13,"profit":true},{"date":"2021-12-31","value":81.48,"profit":true},{"date":"2022-12-31","value":83.09,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit300.98M348.29M360.70M396.47M475.89M[{"date":"2019-12-31","value":63.25,"profit":true},{"date":"2020-12-31","value":73.19,"profit":true},{"date":"2021-12-31","value":75.79,"profit":true},{"date":"2022-12-31","value":83.31,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin98.20%98.42%98.56%98.66%98.66%[{"date":"2019-12-31","value":99.54,"profit":true},{"date":"2020-12-31","value":99.76,"profit":true},{"date":"2021-12-31","value":99.9,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Expenses189.38M220.09M236.22M283.84M368.61M[{"date":"2019-12-31","value":51.38,"profit":true},{"date":"2020-12-31","value":59.71,"profit":true},{"date":"2021-12-31","value":64.08,"profit":true},{"date":"2022-12-31","value":77,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income111.61M128.20M124.48M112.63M107.28M[{"date":"2019-12-31","value":87.05,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":97.09,"profit":true},{"date":"2022-12-31","value":87.86,"profit":true},{"date":"2023-12-31","value":83.68,"profit":true}]
Total Non-Operating Income/Expense10.14M6.80M1.06M7.11M34.55M[{"date":"2019-12-31","value":29.35,"profit":true},{"date":"2020-12-31","value":19.68,"profit":true},{"date":"2021-12-31","value":3.06,"profit":true},{"date":"2022-12-31","value":20.59,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income116.68M131.60M125.01M116.19M124.56M[{"date":"2019-12-31","value":88.66,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":94.99,"profit":true},{"date":"2022-12-31","value":88.29,"profit":true},{"date":"2023-12-31","value":94.65,"profit":true}]
Income Taxes22.50M25.59M12.49M14.77M18.42M[{"date":"2019-12-31","value":87.9,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":48.82,"profit":true},{"date":"2022-12-31","value":57.73,"profit":true},{"date":"2023-12-31","value":71.97,"profit":true}]
Income After Taxes94.18M106.01M112.51M101.42M106.14M[{"date":"2019-12-31","value":83.71,"profit":true},{"date":"2020-12-31","value":94.22,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":90.14,"profit":true},{"date":"2023-12-31","value":94.34,"profit":true}]
Income From Continuous Operations94.18M106.01M112.51M101.42M106.14M[{"date":"2019-12-31","value":83.71,"profit":true},{"date":"2020-12-31","value":94.22,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":90.14,"profit":true},{"date":"2023-12-31","value":94.34,"profit":true}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income94.18M106.01M112.51M101.42M106.14M[{"date":"2019-12-31","value":83.71,"profit":true},{"date":"2020-12-31","value":94.22,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":90.14,"profit":true},{"date":"2023-12-31","value":94.34,"profit":true}]
EPS (Diluted)0.780.850.890.880.95[{"date":"2019-12-31","value":82.11,"profit":true},{"date":"2020-12-31","value":89.47,"profit":true},{"date":"2021-12-31","value":93.68,"profit":true},{"date":"2022-12-31","value":92.63,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

CORT
Cash Ratio 3.01
Current Ratio 3.70
Quick Ratio 3.64

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

CORT
ROA (LTM) 13.00%
ROE (LTM) 25.77%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

CORT
Debt Ratio Lower is generally better. Negative is bad. 0.19
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.81

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

CORT
Trailing PE 40.40
Forward PE 28.25
P/S (TTM) 8.48
P/B 8.44
Price/FCF 74
EV/R 7.98
EV/Ebitda 34.70
PEG 0.61

FAQs

What is Corcept Therapeutics Incorporated share price today?

Corcept Therapeutics Incorporated (CORT) share price today is $52.17

Can Indians buy Corcept Therapeutics Incorporated shares?

Yes, Indians can buy shares of Corcept Therapeutics Incorporated (CORT) on Vested. To buy Corcept Therapeutics Incorporated from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CORT stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Corcept Therapeutics Incorporated be purchased?

Yes, you can purchase fractional shares of Corcept Therapeutics Incorporated (CORT) via the Vested app. You can start investing in Corcept Therapeutics Incorporated (CORT) with a minimum investment of $1.

How to invest in Corcept Therapeutics Incorporated shares from India?

You can invest in shares of Corcept Therapeutics Incorporated (CORT) via Vested in three simple steps:

  • Click on Sign Up or Invest in CORT stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Corcept Therapeutics Incorporated shares
What is Corcept Therapeutics Incorporated 52-week high and low stock price?

The 52-week high price of Corcept Therapeutics Incorporated (CORT) is $62.22. The 52-week low price of Corcept Therapeutics Incorporated (CORT) is $20.84.

What is Corcept Therapeutics Incorporated price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Corcept Therapeutics Incorporated (CORT) is 40.3968

What is Corcept Therapeutics Incorporated price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Corcept Therapeutics Incorporated (CORT) is 8.44

What is Corcept Therapeutics Incorporated dividend yield?

The dividend yield of Corcept Therapeutics Incorporated (CORT) is 0.00%

What is the Market Cap of Corcept Therapeutics Incorporated?

The market capitalization of Corcept Therapeutics Incorporated (CORT) is $5.33B

What is Corcept Therapeutics Incorporated’s stock symbol?

The stock symbol (or ticker) of Corcept Therapeutics Incorporated is CORT

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top